Key statistics
On Monday, Vanda Pharmaceuticals Inc (VNDA:NMQ) closed at 8.17, -14.90% below its 52-week high of 9.60, set on Dec 31, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 8.66 |
|---|---|
| High | 8.82 |
| Low | 8.08 |
| Bid | 8.14 |
| Offer | 8.25 |
| Previous close | 8.91 |
| Average volume | 7.76m |
|---|---|
| Shares outstanding | 59.11m |
| Free float | 52.40m |
| P/E (TTM) | -- |
| Market cap | 482.91m USD |
| EPS (TTM) | -3.74 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
- Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
- Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
- Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation
- Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
- Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
- Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
- Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
- Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
- Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
More ▼
